Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jill Broadfoot was appointed as Director at Cue Biopharma, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Kerri-Ann Millar departed as Chief Financial Officer at Cue Biopharma, Inc..
- Action
- resigning
- Role
- Chief Financial Officer
Exact text from the filing
On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Daniel R. Passeri changed role as principal financial and accounting officer at Cue Biopharma, Inc..
- Action
- will serve as
- Role
- principal financial and accounting officer
Exact text from the filing
Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Cue Biopharma, Inc.: Increased authorized shares of capital stock from 210,000,000 to 310,000,000 and common stock from 200,000,000 to 300,000,000 (effective 2025-06-05).
- Change
- charter amendment
- Effective
- 2025-06-05
Exact text from the filing
On June 5, 2025, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company’s capital stock from 210,000,000 to 310,000,000 and increase the number of authorized shares of the Company’s common stock from 200,000,000 to 300,000,000.
View on SEC.gov